The U.S. Food and Drug Administration has given the approval to Watson Pharmaceuticals, Inc.’s RAPAFLO(TM) (silodosin), the novel alpha blocker to be used for treating the symptoms of Benign Prostatic Hyperplasia (BPH). The disorder is characterized by prostate problems such as decline in urine flow, nocturia and frequent urination. RAPAFLO binds to the alpha (1A) receptors, with high affinity, that are concentrated in the prostate. This smoothens the muscles in these tissues. As they get to relax, urine flow improves.